Yaz

Bayer suing over controversial birth control

Bloomberg reports that a unit of Bayer is suing generic drug manufacturer Watson Pharmaceuticals Inc. over allegations that Watson has violated a patent for Beyaz birth control pills.

A spokesman for New Jersey-based Watson said the company intends to contest Bayer’s claims.

Bayer has requested that a judge ban the sale of birth control pills based on the patent.

Beyaz and other birth control pills containing the compound drospirenone has served as the basis of read more.... --> continue reading...

New pharmaceuticals boost profits for Bayer

German corporation Bayer will rely on commercialization of its new pharmaceutical products to bolster its profits in the year ahead.

A recent report by the corporate giant trumpets its sales in the past year, stating they rose by 4.1 percent in 2011 to $48.2 million. The report specifically mentions Bayer’s HeathCare subgroup, responsible for pharmaceutical products, as contributing to the profitability.

“One of our strengths continues to be our well-stocked development pipeline in pharmaceuticals,” Bayer CEO Dr. Marijn Dekkers said. Several times, ...

continue reading...

Woman’s infertility blamed on Yaz

Indiana TV station WTHR recently ran a segment about the birth control pill Yaz, manufactured by Bayer.

The report spotlights Indianapolis-area resident Linda Rosenberg, who is no longer able to conceive children as a result of treatment she received for a blood clot in her ankle. Rosenberg suffered the blood clot after taking Yaz, which numerous studies have linked to blood clots.

WTHR report notes that 50 patients have reportedly died from taking Yaz, Yasmin, and Beyaz, and thousands of others have ...

continue reading...

FDA to study misleading ads such as the 2007-2008 Yaz commercials

The federal Food and Drug Administration will study the impact of “corrective” advertising on consumers’ false perceptions of drug safety and effectiveness.

In a notice posted to the Feb. 29 Federal Register, the agency cited ads run by Bayer in 2009 at FDA’s behest to correct false or misleading claims and omissions it had made when advertising Yaz.

But the agency said: “researchers and policymakers currently lack exhaustive empirical literature regarding the various impacts of corrective (direct-to-consumer) advertisements on prescription drug consumers. ...

continue reading...

Another delay in Yasmin case

For the second time in three months, the U.S. District Court has delayed trial deadlines in the cases over Yaz/Yasmin/Beyaz birth control for 60 days.

Chief Judge David R. Herndon of the Southern District of Illinois announced the delay on Feb. 29. The delay will allow the parties in the case more time to negotiate.

Lopez McHugh is representing multiple plaintiffs against Bayer Healthcare, manufacturer of the birth control pills Yasmin, Yaz, Beyaz, and Ocella. Lopez McHugh’s claim, supported by a ...

continue reading...

FDA Panel: Yaz/Yasmin Birth Control Labeling Should Reflect Risks

A Food and Drug Administration panel of experts ruled that the labeling of the popular birth-control pills Yaz and Beyaz should be updated to reflect recent data showing the drug poses a higher risk of causing blood clots than older contraceptives.

Already, 10,458 lawsuits have been filed in federal court against pharmaceutical giant Bayer AG, maker of the contraceptives Yaz, Beyaz, and Yasmin. Plaintiffs claim they weren’t warned of the drug’s harmful side effects, according to the Southern District of ...

continue reading...
Page 28 of 30 «...10202627282930